<DOC>
	<DOCNO>NCT02973776</DOCNO>
	<brief_summary>Vasoconstriction study LEO 90100</brief_summary>
	<brief_title>Vasoconstriction Trial With LEO 90100 Aerosol Foam</brief_title>
	<detailed_description>This study compare pharmacodynamic activity LEO 90100 Dermovate cream , Diprosone ointment , Elocon cream , Locoid ointment LEO 90100 vehicle use human skin blanching test</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Hydrocortisone-17-butyrate</mesh_term>
	<criteria>Subjects demonstrate adequate vasoconstriction Diprosone® ointment within 15 day prior dose ( unoccluded application Diprosone® ointment 46 hour must show visual score skin blanch least one unit ( visual scale ( 04 ) ) . Subjects without sign skin irritation/disease/disorders/symptoms blemish test site ( e.g . erythema , dryness , roughness , scaling , scar , mole , sunburn ) . Abnormal pigmentation skin skin type could , way , confound interpretation trial result ( skin type V VI Fitzpatrick scale ) . Female subject breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>